Correction to Remdesivir: A Review of Its Discovery and Development Leading to Human Clinical Trials for Treatment of COVID-19
Authors:
- Richard T. EastmanRERichard T. Eastman
- Jacob S. RothJRJacob S. Roth
- Kyle R. BrimacombeKBKyle R. Brimacombe
- Anton SimeonovASAnton Simeonov
- Min ShenMSMin Shen
- Samarjit PatnaikSPSamarjit Patnaik
- Matthew D. HallMHMatthew D. Hall
- 16 June 2020
- journal article
- correction
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 6 (6) , 1009
Abstract
[This corrects the article DOI: 10.1021/acscentsci.0c00489.].Keywords
This publication has 3 references indexed in Scilit:
- Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategiesNature Communications, 2018
- Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading ExoribonucleasemBio, 2018
- Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeysNature, 2016